Abstract
Introduction
Materials and methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Surgical OncologyReferences
- Global Cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.C.A. Cancer J. Clin. 2018; 68: 394-424https://doi.org/10.3322/caac.21492
- Colorectal cancer: metastases to a single organ.World J Gastroenterol. 2015; 21: 11767-11776https://doi.org/10.3748/wjg.v21.i41.11767
National Comprehensive Cancer Network; Cancer, C., 1.2021 version. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf, (accessed 19 May 2021).
- Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases.Ann Thorac Surg. 2009; 87: 1684-1688https://doi.org/10.1016/j.athoracsur.2009.03.034
- Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.Eur J Cancer. 2015; 51: 166-176https://doi.org/10.1016/j.ejca.2014.10.023
- Primary tumor resection for stage IV colorectal cancer in the era of targeted chemotherapy.J Gastrointest Surg. 2019; 23: 2144-2150https://doi.org/10.1007/s11605-018-4044-y
- Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.Ann Oncol. 2013; 24: 2342-2349https://doi.org/10.1093/annonc/mdt231
- Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon.Ann Plast Surg. 2013; 71: 434-440https://doi.org/10.1097/SAP.0b013e31824e5e57
- Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.J Cancer Res Clin Oncol. 2020; 146: 2399-2410https://doi.org/10.1007/s00432-020-03233-7
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.J Surg Oncol. 2005; 91: 173-180https://doi.org/10.1002/jso.20301
- Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.Ann Surg Oncol. 2007; 14: 759-765https://doi.org/10.1245/s10434-006-9074-0
- Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.J Clin Oncol. 2008; 26: 5254-5260https://doi.org/10.1200/JCO.2008.17.7857
- Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.Anticancer Res. 2015; 35: 2255-2261
- Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.J Gastrointest Surg. 2013; 17: 527-532https://doi.org/10.1007/s11605-012-2108-y
- Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.Clin Colorectal Cancer. 2013; 12: 15-22https://doi.org/10.1016/j.clcc.2012.07.002
- Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.Lancet Oncol. 2010; 11: 373-382https://doi.org/10.1016/S1470-2045(09)70341-9
- Colorectal cancer emergencies.J Gastrointest Cancer. 2013; 44: 132-142https://doi.org/10.1007/s12029-012-9468-0
- Emergency presentation of colon cancer is most frequent during summer.Colorectal Dis. 2011; 13: 663-668https://doi.org/10.1111/j.1463-1318.2010.02270.x
Bureau of National Health Insurance in Taiwan. The Drugs Payment Guideline for Anti-Neoplastic Agents. https://www.nhi.gov.tw/DL.aspx?sitessn=292&u=LzAwMS9VcGxvYWQvMjkyL3JlbGZpbGUvMC82MTM3L2NoYXA5XzExMDExLnBkZg%3d%3d&n=Y2hhcDlfMTEwMTEucGRm&ico%20=.pdf, (accessed 24 Dec 2020).
- http://nhird.nhri.org.tw/en/index.htm([Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan])Date accessed: December 24, 2020
- Taiwan's national Health insurance research database: past and future.Clin Epidemiol. 2019; 11: 349-358https://doi.org/10.2147/CLEP.S196293
- Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review.Jpn J Clin Oncol. 2015; 45: 291-296https://doi.org/10.1093/jjco/hyu211
- The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients.J Clin Epidemiol. 2008; 61: 1234-1240https://doi.org/10.1016/j.jclinepi.2008.01.006
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.J Clin Epidemiol. 1992; 45: 613-619https://doi.org/10.1016/0895-4356(92)90133-8
- Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.Br J Surg. 2006; 93: 1456-1463https://doi.org/10.1002/bjs.5624
- The role of vascular endothelial growth factor in wound healing.J Surg Res. 2009; 153: 347-358https://doi.org/10.1016/j.jss.2008.04.023
- Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.Br J Cancer. 2012; 107: 961-966https://doi.org/10.1038/bjc.2012.342
- Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.J Clin Oncol. 2001; 19: 843-850https://doi.org/10.1200/JCO.2001.19.3.843
- Evaluation of the patients with colorectal cancer undergoing emergent curative surgery.SpringerPlus. 2016; 5: 2024https://doi.org/10.1186/s40064-016-3725-9
- Mortality following emergency laparotomy: a Swedish cohort study.BMC Surg. 2021; 21: 322https://doi.org/10.1186/s12893-021-01319-8
- A nationwide analysis of readmission rates after colorectal cancer surgery in the US in the Era of the Addordable Care Act.Am J Surg. 2020; 220: 1015-1022https://doi.org/10.1016/j.amjsurg.2020.04.013
- A population-based study of complications after colorectal surgery in patients who have received bevacizumab.Dis Colon Rectum. 2018; 61: 306-313https://doi.org/10.1097/DCR.0000000000000966
- Review: incidence and clinical significance of bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.Eur J Surg Oncol. 2011; 37: 737-746https://doi.org/10.1016/j.ejso.2011.06.004
- Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.Oncol. 2009; 14: 862-870https://doi.org/10.1634/theoncologist.2009-0071
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.Ann Oncol. 2009; 20: 1842-1847https://doi.org/10.1093/annonc/mdp233
- Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.Br J Surg. 2011; 98: 399-407https://doi.org/10.1002/bjs.7368
- A NSQIP review of major morbidity and mortality of synchronous liver resection for colorectal metastasis stratified by extent of liver resection and type of colorectal resection.J Gastrointest Surg. 2015; 19: 1982-1994https://doi.org/10.1007/s11605-015-2895-z